Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06704152 · ClinicalTrials.gov registry record · Phase 1
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
A Phase 1 study of MDS and AML, Adult Recurrent, sponsored by BlueSphere Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 6
- Study locations
NCT06704152 is a Phase 1 study of MDS and AML, Adult Recurrent that is actively recruiting participants, run by BlueSphere Bio. The registered enrollment target is 38 participants, below the 95-participant average among 22 other MDS trials with a reported enrollment target (60% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT06704152, a Phase 1 study of MDS and AML, Adult Recurrent, is actively recruiting participants, sponsored by BlueSphere Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this clinical trial is to test BSB-1001 which is a new type of cellular therapy to treat blood cancers (AML, ALL and MDS). It will evaluate the safety of BSB-1001 and also determine whether it works to prevent relapse of your cancer.
Conditions Studied
Interventions
- DRUG SOC + BSB-1001 Dose Escalation Cohort
- DRUG SOC+BSB-1001 Expansion Dose
Study Locations (6)
California
- City of Hope National Medical Center - Duarte
Florida
- Moffitt Cancer Center - Tampa
Michigan
- University of Michigan - Ann Arbor
Minnesota
- University of Minnesota - Minneapolis
Missouri
- Washington University at St Louis - St Louis
Ohio
- The Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2025-02-04 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06704152
The ClinicalTrials.gov registry entry for NCT06704152 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 22 other MDS trials with a reported enrollment target (60% lower). The listed sponsor is BlueSphere Bio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with MDS appearing as the primary indexed condition, and to 2 interventions - of which SOC + BSB-1001 Dose Escalation Cohort is the first listed.
NCT06704152 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT06704152 about?
NCT06704152 is a clinical study titled "BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS". The goal of this clinical trial is to test BSB-1001 which is a new type of cellular therapy to treat blood cancers (AML, ALL and MDS). It will evaluate the safety of BSB-1001 and also determine whether it works to prevent relapse of your cancer.
What is the current status of trial NCT06704152?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2025-02-04. Estimated completion is 2029-03.
What conditions does trial NCT06704152 study?
This clinical trial studies the following conditions: MDS, AML, Adult Recurrent, ALL, Recurrent, Adult.
What interventions are being tested in trial NCT06704152?
The interventions under investigation include: SOC + BSB-1001 Dose Escalation Cohort (DRUG), SOC+BSB-1001 Expansion Dose (DRUG).
Who is sponsoring clinical trial NCT06704152?
This trial is sponsored by BlueSphere Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06704152 being conducted?
This trial has 6 study locations across California, Florida, Michigan, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for MDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 1
-
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 1
-
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.